Aptose Biosciences (APTO) Peer Comparison
$2.03
$0.02
(1.00%)
As on 01-May-2025 09:30EDT
Market cap
$4 Mln
Revenue (TTM)
$1 Mln
P/E Ratio
--
P/B Ratio
67.8
Div. Yield
0 %
Edit
| Aptose Biosciences (APTO) | Mind Medicine Inc (MNMD) | Bright Minds Biosciences Inc (DRUG) | Cybin (CYBN) | Oncolytics Biotech - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
4 | 1,460 | 760 | 413 | 108 |
Revenue ($ Mln) |
-- | -- | -- | -- | -- |
Net Profit ($ Mln) |
-25.43 | -168.10 | -24.75 | -131.58 | -38.21 |
Net Margin (%) |
-2,662.08 | -- | -- | -- | -- |
RoE (%) |
683.23 | -95.13 | -12.45 | -61.82 | -- |
Price to Earnings |
-- | -- | -- | -- | -- |
Price-To-Book |
67.84 | 12.91 | 3.48 | 1.03 | 1,055.04 |
Cashflow ($ Mln)
| Aptose Biosciences (APTO) | Mind Medicine Inc (MNMD) | Bright Minds Biosciences Inc (DRUG) | Cybin (CYBN) | Oncolytics Biotech - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-35.98 | -79.13 | -1.85 | -68.91 | -19.88 |
|
Cash Flow from Investing Activities
|
-- | -- | -- | 6.92 | -0.17 |
|
Cash from Financing Activities
|
33.41 | 253.20 | 0.81 | 254.51 | 5.03 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Aptose Biosciences (APTO) | Mind Medicine Inc (MNMD) | Bright Minds Biosciences Inc (DRUG) | Cybin (CYBN) | Oncolytics Biotech - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
875.69 | -61.13 | -45.46 | -42.39 | -130.13 |
|
ROE (%)
|
683.23 | -68.01 | -46.18 | -42.43 | -135.90 |
|
ROA (%)
|
-220.02 | -50.94 | -43.16 | -40.45 | -77.26 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
-- | -- | -- | -- | -- |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| Aptose Biosciences (APTO) | Mind Medicine Inc (MNMD) | Bright Minds Biosciences Inc (DRUG) | Cybin (CYBN) | Oncolytics Biotech - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
50.34 | -13.52 | 61.99 | -95.02 | -8.96 |
|
EPS Growth (%)
|
-- | 0.46 | 0.69 | -2.01 | 0.00 |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| Aptose Biosciences (APTO) | Mind Medicine Inc (MNMD) | Bright Minds Biosciences Inc (DRUG) | Cybin (CYBN) | Oncolytics Biotech - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
-- | -5.38 | -1.94 | -0.67 | -3.21 |
|
Price / Book Value
|
-- | 2.42 | 0.98 | 0.18 | 12.22 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-- | -3.14 | 0.06 | 1.99 | -2.29 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Aptose Biosciences (APTO) | Mind Medicine Inc (MNMD) | Bright Minds Biosciences Inc (DRUG) | Cybin (CYBN) | Oncolytics Biotech - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-0.14 | 0.09 | 0.02 | 0.00 | 0.18 |
|
Short term debt to equity ratio
|
-0.09 | -- | 0.01 | 0.00 | 0.05 |
|
Current Ratio
|
2.14 | 7.25 | 11.32 | 21.65 | 2.82 |
|
Quick Ratio
|
-- | -- | -- | 22.09 | -- |
|
Interest Coverage
|
-- | -46.60 | -- | -- | -- |
Operating Efficiency Ratios
| Aptose Biosciences (APTO) | Mind Medicine Inc (MNMD) | Bright Minds Biosciences Inc (DRUG) | Cybin (CYBN) | Oncolytics Biotech - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | -- | -- | -- | -- |
|
Asset Turnover
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Receivable days
|
-- | -- | -- | -- | -- |
|
Inventory Days
|
-- | -- | -- | -1,380.46 | -- |
|
Payable days
|
-- | 2,129.82 | -- | 6,662.37 | 4,553.03 |
|
Cash Conversion Cycle
|
-- | -- | -- | -- | -- |
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
